Maze Therapeutics appoints Paula Johnson and Sophie Kornowski to board; pipeline milestones ahead

Maze Therapeutics, Inc.

Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., appointed to Maze's board effective Aug 13, 2026.
Johnson is President of Wellesley College and J&J board member; Kornowski ex-CEO of Boston Pharmaceuticals, led GSK acquisition.
Board class changes: Nancy Andrews moved to Class II, Hervé Hoppenot to Class III to balance classes.
CEO Jason Coloma cites upcoming data: MZE829 in AMKD late 2026/early 2027, MZE782 initial data in 2027.
Each new director receives pro-rata $40k cash retainer and option for 36,000 shares vesting monthly over 3 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.